Paper Details

  1. Home
  2. Paper Details

Induction therapy of loco-regional non-small-cell lung cancer with reliable response and low toxicity (low dose radiotherapy sensitizes tumor to subsequent chemotherapy?).

Author: ShinKyu H, SohAndrew Y, TakitaHiroshi, WildingGreg, YiWon S

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

The regimen of 20Gy radiation followed by two courses of chemotherapy consisting of paclitaxel, cisplatin, and ifosfamide is a suitable regimen for induction therapy for early-stage resectable non-small-cell lung cancers.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: For the induction therapy of non-small-cell lung cancer, we need to look for a regimen which produces a reliable high response rate with a low treatment related morbidity and mortality. METHODS: Patients in clinical stages IB, IIA and B, IIIA and B received a course of therapy with 20...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.lungcan.2008.06.010

データ提供：米国国立医学図書館（NLM）

Induction Therapy for Loco-Regional Non-Small-Cell Lung Cancer

This study explores a novel approach to treating non-small-cell lung cancer (NSCLC), a common type of lung cancer. The study investigates the efficacy of a combined treatment strategy involving low-dose radiotherapy followed by chemotherapy in patients with loco-regional NSCLC. The researchers aimed to determine whether this regimen could achieve a high response rate with minimal side effects.

Low-Dose Radiotherapy Sensitized Tumors to Chemotherapy

The study found that the combination of low-dose radiotherapy and chemotherapy led to an impressive overall response rate of 82.86%. The study also demonstrated that the treatment regimen was well tolerated, with a low incidence of severe side effects. These findings suggest that this combined approach holds promise as a more effective and less toxic treatment option for loco-regional NSCLC.

Hope on the Horizon for Lung Cancer Treatment

This study is a welcome oasis in the desert of lung cancer research. It suggests that new approaches may be more effective and less burdensome for patients. This research inspires hope for the development of better treatments for lung cancer.

Dr.Camel's Conclusion

This research offers promising results for the treatment of non-small-cell lung cancer. It's a reminder that innovation and collaboration are key to making progress in the fight against cancer.

Date :
  1. Date Completed 2009-04-08
  2. Date Revised 2009-02-09
Further Info :

Pubmed ID

18676056

DOI: Digital Object Identifier

10.1016/j.lungcan.2008.06.010

Related Literature

Article Analysis
・Effective treatment of lung cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.